{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:37:10Z","timestamp":1786981030704,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10637-012-9810-1","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T06:15:44Z","timestamp":1331619344000},"page":"2274-2283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias"],"prefix":"10.1007","volume":"30","author":[{"given":"Patrick","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhama","family":"Chahoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"P\u00e4llman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Braig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"Wiehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kolodzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rarey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Balabanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"issue":"5","key":"9810_CR1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood.V65.5.1039.1039","volume":"65","author":"RE Champlin","year":"1985","unstructured":"Champlin RE, Golde DW (1985) Chronic myelogenous leukemia: recent advances. Blood 65(5):1039\u20131047","journal-title":"Blood"},{"key":"9810_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev.cellbio.22.010305.104154","volume":"23","author":"NA Lobo","year":"2007","unstructured":"Lobo NA et al (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675\u2013699","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"2 Suppl 2","key":"9810_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/shem.2003.50034","volume":"40","author":"M Sattler","year":"2003","unstructured":"Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40(2 Suppl 2):4\u201310","journal-title":"Semin Hematol"},{"issue":"10","key":"9810_CR4","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99(10):3530\u20133539","journal-title":"Blood"},{"issue":"6","key":"9810_CR5","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99(6):1928\u20131937","journal-title":"Blood"},{"issue":"11","key":"9810_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004","journal-title":"N Engl J Med"},{"issue":"7","key":"9810_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R et al (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1(7):493\u2013502","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"9810_CR8","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7):2640\u20132653","journal-title":"Blood"},{"issue":"1","key":"9810_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","volume":"16","author":"T O\u2019Hare","year":"2006","unstructured":"O\u2019Hare T, Corbin AS, Druker BJ (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16(1):92\u201399","journal-title":"Curr Opin Genet Dev"},{"issue":"4","key":"9810_CR10","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood-2005-03-037648","volume":"109","author":"S Balabanov","year":"2007","unstructured":"Balabanov S et al (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109(4):1701\u20131711","journal-title":"Blood"},{"issue":"12","key":"9810_CR11","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1016\/S0021-9258(18)34559-9","volume":"257","author":"MH Park","year":"1982","unstructured":"Park MH, Cooper HL, Folk JE (1982) The biosynthesis of protein-bound hypusine (N epsilon -(4-amino-2-hydroxybutyl)lysine). lysine as the amino acid precursor and the intermediate role of deoxyhypusine (N epsilon -(4-aminobutyl)lysine). J Biol Chem 257(12):7217\u20137222","journal-title":"J Biol Chem"},{"issue":"34","key":"9810_CR12","doi-asserted-by":"crossref","first-page":"16585","DOI":"10.1016\/S0021-9258(18)49296-4","volume":"262","author":"ED Gordon","year":"1987","unstructured":"Gordon ED et al (1987) Eukaryotic initiation factor 4D, the hypusine-containing protein, is conserved among eukaryotes. J Biol Chem 262(34):16585\u201316589","journal-title":"J Biol Chem"},{"issue":"2","key":"9810_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1432-1033.1992.tb16690.x","volume":"204","author":"D Bartig","year":"1992","unstructured":"Bartig D et al (1992) The archaebacterial hypusine-containing protein. Structural features suggest common ancestry with eukaryotic translation initiation factor 5A. Eur J Biochem 204(2):751\u2013758","journal-title":"Eur J Biochem"},{"key":"9810_CR14","doi-asserted-by":"crossref","unstructured":"Li CH et al. eIF5A promotes translation elongation, polysome disassembly and stress granule assembly. PLoS One 5(4):e9942.","DOI":"10.1371\/journal.pone.0009942"},{"issue":"9","key":"9810_CR15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1084\/jem.191.9.1581","volume":"191","author":"M Kruse","year":"2000","unstructured":"Kruse M et al (2000) Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J Exp Med 191(9):1581\u20131590","journal-title":"J Exp Med"},{"key":"9810_CR16","doi-asserted-by":"crossref","unstructured":"Maier B et al. The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest 120(6): 2156\u201370.","DOI":"10.1172\/JCI38924"},{"issue":"1","key":"9810_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/viro.2002.1659","volume":"304","author":"RA Hart","year":"2002","unstructured":"Hart RA et al (2002) Effects of 1,8-diaminooctane on the FIV Rev regulatory system. Virology 304(1):97\u2013104","journal-title":"Virology"},{"issue":"5","key":"9810_CR18","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1128\/jvi.69.5.3125-3133.1995","volume":"69","author":"J Katahira","year":"1995","unstructured":"Katahira J et al (1995) Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding. J Virol 69(5):3125\u20133133","journal-title":"J Virol"},{"issue":"5","key":"9810_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1087057104264031","volume":"9","author":"MN Sommer","year":"2004","unstructured":"Sommer MN et al (2004) Screening assay for the identification of deoxyhypusine synthase inhibitors. J Biomol Screen 9(5):434\u2013438","journal-title":"J Biomol Screen"},{"issue":"1","key":"9810_CR20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1172\/JCI200521949","volume":"115","author":"I Hauber","year":"2005","unstructured":"Hauber I et al (2005) Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 115(1):76\u201385","journal-title":"J Clin Invest"},{"issue":"Pt 3","key":"9810_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1042\/0264-6021:3630761","volume":"363","author":"K Nishimura","year":"2002","unstructured":"Nishimura K et al (2002) Inhibition of cell growth through inactivation of eukaryotic translation initiation factor 5A (eIF5A) by deoxyspergualin. Biochem J 363(Pt 3):761\u2013768","journal-title":"Biochem J"},{"issue":"3","key":"9810_CR22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF03401550","volume":"1","author":"M Bianchi","year":"1995","unstructured":"Bianchi M et al (1995) An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol Med 1(3):254\u2013266","journal-title":"Mol Med"},{"issue":"1","key":"9810_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1021\/jm00367a007","volume":"27","author":"P Ulrich","year":"1984","unstructured":"Ulrich P, Cerami A (1984) Trypanocidal 1,3-arylene diketone bis(guanylhydrazone)s. Structure-activity relationships among substituted and heterocyclic analogues. J Med Chem 27(1):35\u201340","journal-title":"J Med Chem"},{"key":"9810_CR24","doi-asserted-by":"crossref","unstructured":"Balabanov S et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One 6(4): e19164.","DOI":"10.1371\/journal.pone.0019164"},{"issue":"2","key":"9810_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","volume":"103","author":"K Bartolovic","year":"2004","unstructured":"Bartolovic K et al (2004) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103(2):523\u2013529","journal-title":"Blood"},{"issue":"8","key":"9810_CR26","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","volume":"111","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz A et al (2008) Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111(8):4355\u20134364","journal-title":"Blood"},{"issue":"5","key":"9810_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.exphem.2005.02.002","volume":"33","author":"U Hartmann","year":"2005","unstructured":"Hartmann U et al (2005) Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. Exp Hematol 33(5):542\u2013549","journal-title":"Exp Hematol"},{"issue":"12","key":"9810_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0968-0004(93)90010-K","volume":"18","author":"MH Park","year":"1993","unstructured":"Park MH, Wolff EC, Folk JE (1993) Is hypusine essential for eukaryotic cell proliferation? Trends Biochem Sci 18(12):475\u2013479","journal-title":"Trends Biochem Sci"},{"issue":"21","key":"9810_CR29","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1046\/j.1432-1033.2003.03806.x","volume":"270","author":"PM Clement","year":"2003","unstructured":"Clement PM et al (2003) Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem 270(21):4254\u20134263","journal-title":"Eur J Biochem"},{"issue":"6","key":"9810_CR30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1742-4658.2006.05135.x","volume":"273","author":"PM Clement","year":"2006","unstructured":"Clement PM et al (2006) Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J 273(6):1102\u20131114","journal-title":"FEBS J"},{"issue":"Pt 3","key":"9810_CR31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1042\/BJ20041477","volume":"385","author":"K Nishimura","year":"2005","unstructured":"Nishimura K et al (2005) Independent roles of eIF5A and polyamines in cell proliferation. Biochem J 385(Pt 3):779\u2013785","journal-title":"Biochem J"},{"issue":"47","key":"9810_CR32","doi-asserted-by":"publisher","first-page":"49251","DOI":"10.1074\/jbc.M407165200","volume":"279","author":"AL Li","year":"2004","unstructured":"Li AL et al (2004) A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem 279(47):49251\u201349258","journal-title":"J Biol Chem"},{"issue":"7","key":"9810_CR33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/annonc\/mdn050","volume":"19","author":"R Capdeville","year":"2008","unstructured":"Capdeville R et al (2008) Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Ann Oncol 19(7):1320\u20131326","journal-title":"Ann Oncol"},{"issue":"6","key":"9810_CR34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054\u20131061","journal-title":"Leukemia"},{"key":"9810_CR35","first-page":"93","volume":"125","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 125:93\u2013106","journal-title":"Methods Mol Med"},{"issue":"3","key":"9810_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11899-996-0002-y","volume":"1","author":"JA Zonder","year":"2006","unstructured":"Zonder JA, Schiffer CA (2006) Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Curr Hematol Malig Rep 1(3):141\u2013151","journal-title":"Curr Hematol Malig Rep"},{"key":"9810_CR37","doi-asserted-by":"crossref","unstructured":"O\u2019Hare T et al. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17(2): 212\u201321.","DOI":"10.1158\/1078-0432.CCR-09-3314"},{"issue":"12","key":"9810_CR38","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.7164\/antibiotics.35.1665","volume":"35","author":"H Iwasawa","year":"1982","unstructured":"Iwasawa H et al (1982) Synthesis of (\u2212)-15-deoxyspergualin and (\u2212)-spergualin-15-phosphate. J Antibiot (Tokyo) 35(12):1665\u20131669","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"9810_CR39","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/00007890-199110000-00003","volume":"52","author":"LA Valdivia","year":"1991","unstructured":"Valdivia LA et al (1991) Suppressor cells induced by donor-specific transfusion and deoxyspergualin in rat cardiac xenografts. Transplantation 52(4):594\u2013599","journal-title":"Transplantation"},{"issue":"1","key":"9810_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/gast.2002.30770","volume":"122","author":"D Hommes","year":"2002","unstructured":"Hommes D et al (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn\u2019s disease. Gastroenterology 122(1):7\u201314","journal-title":"Gastroenterology"},{"key":"9810_CR41","doi-asserted-by":"crossref","unstructured":"Sun Z et al. Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. J Cell Physiol 223(3): 798\u2013809.","DOI":"10.1002\/jcp.22100"},{"key":"9810_CR42","doi-asserted-by":"crossref","unstructured":"Saglio G et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24): 2251\u20139.","DOI":"10.1056\/NEJMoa0912614"},{"key":"9810_CR43","doi-asserted-by":"crossref","unstructured":"Kantarjian H et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24): 2260\u201370.","DOI":"10.1056\/NEJMoa1002315"},{"key":"9810_CR44","doi-asserted-by":"crossref","unstructured":"Cortes JE et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17): 4567\u201376.","DOI":"10.1182\/blood-2011-05-355594"},{"issue":"5","key":"9810_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412","journal-title":"Cancer Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9810-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9810-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T06:31:43Z","timestamp":1713681103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["9810"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9810-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]},"assertion":[{"value":"15 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}